FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1885655341> ?p ?o ?g. }

• W1885655341 endingPage "403" @default.
• W1885655341 startingPage "396" @default.
• W1885655341 abstract "What's known on the subject? and What does the study add? A significant proportion of patients diagnosed with prostate cancer do not require immediate treatment and could be managed by active surveillance, which usually includes serial measurements of prostate-specific antigen (PSA) levels and regular biopsies. The rate of rise in PSA levels, which could be calculated as PSA velocity or PSA doubling time, was previously suggested to be associated with the biological aggressiveness of prostate cancer. Although these parameters are obvious candidates for predicting tumour progression in active surveillance patients, earlier studies that examined this topic provided conflicting results. Our analysis showed that PSA velocity and PSA doubling time calculated at different time-points, by different methods, over different intervals, and in different sub-groups of active surveillance patients provide little if any prognostic information. Although we found some significant associations between PSA velocity and the risk of progression as determined by biopsy, the actual clinical significance of this association was small. Furthermore, PSA velocity did not add to the predictive accuracy of total PSA. Objective To study whether prostate-specific antigen (PSA) velocity (PSAV) and PSA doubling time (PSADT) are associated with biopsy progression in patients managed by active surveillance. Patients and Methods Our inclusion criteria for active surveillance are biopsy Gleason sum <7, two or fewer positive biopsy cores, ≤20% tumour present in any core, and clinical stage T1–T2a. Changes in any of these parameters during the follow-up that went beyond these limits are considered to be progression. This study included 250 patients who had at least one surveillance biopsy, an available PSA measured no earlier than 3 months before diagnosis, and at least one PSA measurement before each surveillance biopsy. We evaluated the association between PSA kinetics and progression at successive surveillance biopsies in different sub-groups of patients by calculating the area under the curve (AUC) as well as sensitivity and specificity of different thresholds. Results Over a median follow-up of 3.0 years, the disease of 64 (26%) patients progressed. PSADT was not associated with biopsy progression, whereas PSAV was only weakly associated with progression in certain sub-groups. However, incorporation of PSAV in models including total PSA resulted in a moderate increase in AUC only when the entire cohort was analysed. In other sub-groups the predictive accuracy of total PSA was not significantly improved by adding PSAV. Conclusions Our findings confirm that PSA kinetics should not be used in decision-making in patients with low-risk prostate cancer managed by active surveillance. Regular surveillance biopsies should remain as the principal method of monitoring cancer progression in these men." @default.
• W1885655341 created "2016-06-24" @default.
• W1885655341 creator A5013919495 @default.
• W1885655341 creator A5014456130 @default.
• W1885655341 creator A5027932092 @default.
• W1885655341 creator A5054973221 @default.
• W1885655341 creator A5063670346 @default.
• W1885655341 creator A5082583050 @default.
• W1885655341 date "2012-06-15" @default.
• W1885655341 modified "2023-10-17" @default.
• W1885655341 title "Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients" @default.
• W1885655341 cites W1983145936 @default.
• W1885655341 cites W1987927530 @default.
• W1885655341 cites W1990845638 @default.
• W1885655341 cites W1997746207 @default.
• W1885655341 cites W2023403749 @default.
• W1885655341 cites W2035809577 @default.
• W1885655341 cites W2047651993 @default.
• W1885655341 cites W2055496563 @default.
• W1885655341 cites W2063614609 @default.
• W1885655341 cites W2101266252 @default.
• W1885655341 cites W2107681234 @default.
• W1885655341 cites W2112689533 @default.
• W1885655341 cites W2114709771 @default.
• W1885655341 cites W2132565257 @default.
• W1885655341 cites W2136804662 @default.
• W1885655341 cites W2143858821 @default.
• W1885655341 cites W2145071848 @default.
• W1885655341 cites W2156549595 @default.
• W1885655341 cites W2161435365 @default.
• W1885655341 cites W2161637485 @default.
• W1885655341 cites W3211827789 @default.
• W1885655341 doi "https://doi.org/10.1111/j.1464-410x.2012.11295.x" @default.
• W1885655341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22703025" @default.
• W1885655341 hasPublicationYear "2012" @default.
• W1885655341 type Work @default.
• W1885655341 sameAs 1885655341 @default.
• W1885655341 citedByCount "25" @default.
• W1885655341 countsByYear W18856553412013 @default.
• W1885655341 countsByYear W18856553412014 @default.
• W1885655341 countsByYear W18856553412015 @default.
• W1885655341 countsByYear W18856553412016 @default.
• W1885655341 countsByYear W18856553412018 @default.
• W1885655341 countsByYear W18856553412019 @default.
• W1885655341 countsByYear W18856553412020 @default.
• W1885655341 countsByYear W18856553412023 @default.
• W1885655341 crossrefType "journal-article" @default.
• W1885655341 hasAuthorship W1885655341A5013919495 @default.
• W1885655341 hasAuthorship W1885655341A5014456130 @default.
• W1885655341 hasAuthorship W1885655341A5027932092 @default.
• W1885655341 hasAuthorship W1885655341A5054973221 @default.
• W1885655341 hasAuthorship W1885655341A5063670346 @default.
• W1885655341 hasAuthorship W1885655341A5082583050 @default.
• W1885655341 hasConcept C121608353 @default.
• W1885655341 hasConcept C126322002 @default.
• W1885655341 hasConcept C126894567 @default.
• W1885655341 hasConcept C143998085 @default.
• W1885655341 hasConcept C146357865 @default.
• W1885655341 hasConcept C151730666 @default.
• W1885655341 hasConcept C185592680 @default.
• W1885655341 hasConcept C202751555 @default.
• W1885655341 hasConcept C2775934546 @default.
• W1885655341 hasConcept C2776141087 @default.
• W1885655341 hasConcept C2776235491 @default.
• W1885655341 hasConcept C2780192828 @default.
• W1885655341 hasConcept C2781217009 @default.
• W1885655341 hasConcept C2781406297 @default.
• W1885655341 hasConcept C48900799 @default.
• W1885655341 hasConcept C55493867 @default.
• W1885655341 hasConcept C71924100 @default.
• W1885655341 hasConcept C86803240 @default.
• W1885655341 hasConceptScore W1885655341C121608353 @default.
• W1885655341 hasConceptScore W1885655341C126322002 @default.
• W1885655341 hasConceptScore W1885655341C126894567 @default.
• W1885655341 hasConceptScore W1885655341C143998085 @default.
• W1885655341 hasConceptScore W1885655341C146357865 @default.
• W1885655341 hasConceptScore W1885655341C151730666 @default.
• W1885655341 hasConceptScore W1885655341C185592680 @default.
• W1885655341 hasConceptScore W1885655341C202751555 @default.
• W1885655341 hasConceptScore W1885655341C2775934546 @default.
• W1885655341 hasConceptScore W1885655341C2776141087 @default.
• W1885655341 hasConceptScore W1885655341C2776235491 @default.
• W1885655341 hasConceptScore W1885655341C2780192828 @default.
• W1885655341 hasConceptScore W1885655341C2781217009 @default.
• W1885655341 hasConceptScore W1885655341C2781406297 @default.
• W1885655341 hasConceptScore W1885655341C48900799 @default.
• W1885655341 hasConceptScore W1885655341C55493867 @default.
• W1885655341 hasConceptScore W1885655341C71924100 @default.
• W1885655341 hasConceptScore W1885655341C86803240 @default.
• W1885655341 hasIssue "3" @default.
• W1885655341 hasLocation W18856553411 @default.
• W1885655341 hasLocation W18856553412 @default.
• W1885655341 hasOpenAccess W1885655341 @default.
• W1885655341 hasPrimaryLocation W18856553411 @default.
• W1885655341 hasRelatedWork W1884231116 @default.
• W1885655341 hasRelatedWork W1979374145 @default.
• W1885655341 hasRelatedWork W2038565121 @default.
• W1885655341 hasRelatedWork W2102167265 @default.

• next